IRIS
VESPASIANI GENTILUCCI, UMBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.258
NA - Nord America 1.457
EU - Europa 656
SA - Sud America 35
AF - Africa 29
OC - Oceania 25
Totale 10.460
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 6.705
US - Stati Uniti d'America 1.392
CN - Cina 758
HK - Hong Kong 675
GB - Regno Unito 185
IT - Italia 160
DE - Germania 111
IN - India 45
CA - Canada 44
FI - Finlandia 35
NL - Olanda 34
BR - Brasile 28
CZ - Repubblica Ceca 28
AU - Australia 24
TR - Turchia 22
FR - Francia 19
PL - Polonia 19
JP - Giappone 17
MX - Messico 17
UA - Ucraina 17
ES - Italia 15
ZA - Sudafrica 15
SE - Svezia 6
CH - Svizzera 5
BD - Bangladesh 4
ET - Etiopia 4
ID - Indonesia 4
MA - Marocco 4
SA - Arabia Saudita 4
BE - Belgio 3
CL - Cile 3
IR - Iran 3
LU - Lussemburgo 3
PH - Filippine 3
VN - Vietnam 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
IS - Islanda 2
KR - Corea 2
KZ - Kazakistan 2
LT - Lituania 2
PA - Panama 2
RU - Federazione Russa 2
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BJ - Benin 1
CY - Cipro 1
DK - Danimarca 1
EG - Egitto 1
GH - Ghana 1
GN - Guinea 1
HN - Honduras 1
HT - Haiti 1
HU - Ungheria 1
IE - Irlanda 1
IL - Israele 1
JO - Giordania 1
KI - Kiribati 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MD - Moldavia 1
ML - Mali 1
PE - Perù 1
PY - Paraguay 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
SY - Repubblica araba siriana 1
TL - Timor Orientale 1
UY - Uruguay 1
Totale 10.460
Salva come PNG Salva come JPEG
Città #
Hong Kong 666
Singapore 399
Hefei 391
Ashburn 312
Boardman 216
London 154
Shanghai 134
Dallas 122
Beijing 120
Rome 70
Munich 62
Los Angeles 59
Council Bluffs 54
San Francisco 45
Seattle 31
Brno 28
Pune 26
Santa Clara 25
New York 24
West Jordan 22
Turku 20
Amsterdam 19
Guangzhou 19
Toronto 19
Warsaw 17
Washington 17
Tokyo 16
Helsinki 15
Montreal 14
São Paulo 14
Boston 13
Canberra 12
Mexico City 12
Sona 11
Johannesburg 9
Brooklyn 8
Chennai 8
Chicago 7
Melbourne 7
Paris 7
Shenzhen 7
Atlanta 6
Charlotte 6
Redmond 6
Stockholm 6
Manchester 5
Milan 5
Sydney 5
Zhengzhou 5
Ankara 4
Central 4
Frankfurt am Main 4
Naples 4
Phoenix 4
Secaucus 4
The Dalles 4
Addis Ababa 3
Bari 3
Bologna 3
Brownsville 3
Camden 3
Haikou 3
Kyiv 3
Oklahoma City 3
Providence 3
Rabat 3
Riyadh 3
Shijiazhuang 3
Suzhou 3
Tianjin 3
Valsamoggia 3
Anderlecht 2
Andover 2
Berlin 2
Boydton 2
Buffalo 2
Cervignano del Friuli 2
Cinisello Balsamo 2
Delhi 2
Denver 2
Esch-sur-Alzette 2
Falls Church 2
Ferrara di Monte Baldo 2
Foligno 2
Handan 2
Hangzhou 2
Hanover 2
Helena 2
Houston 2
Jackson 2
Jacksonville 2
Juneau 2
Kharkiv 2
Las Vegas 2
Liverpool 2
Messina 2
Minneapolis 2
Newark 2
Orem 2
Perugia 2
Totale 3.406
Salva come PNG Salva come JPEG
Nome #
Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy 217
Advances in management of periprosthetic joint infections: an historical prospective study 203
A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation 200
A case of Henoch-Schönlein purpura in the elderly: not just a 'second childhood' 200
Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection 198
Anti-tumor necrosis factor-alpha reverts growth hormone resistance associated with inflammatory bowel disease 195
Breath-print analysis by e-nose may refine risk stratification for adverse outcomes in cirrhotic patients 195
Deep vein thrombosis, inferior vena cava interruption and multiple thrombophilic gene mutations 194
Iloprost: an adjunctive approach to chronic viral hepatitis treatment 192
Hepatic Lysosomal Acid Lipase and lipophagy in the progression of NAFLD 189
Impairment of GH/IGF-1 Axis in the liver of patients with hcv-related chronic hepatitis 188
Factors enhancing treatment of hepatitis C virus⇓infected italian people who use drugs: The CLEO-GRECAS experience 187
Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 186
Retroperitoneal fibrosis and ankylosing spondylitis: which links? 185
METAL HOMEOSTASIS IN PATIENTS WITH PORTO-SYSTEMIC ENCEPHALOPATHY 185
Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C 184
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 184
Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study 184
BREATH PRINT ANALYSIS BY E-NOSE IS ASSOCIATED WITH ADVERSE OUTCOMES OF CIRRHOTIC PATIENTS INDEPENDENTLY FROM THE OTHER PROGNOSTIC INDICES 179
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 178
The hepatic expression of lysosomal acid lipase (LAL) is reduced in NAFLD patients, and associated with features of genetically determined LAL deficiency and NAFLD activity score 176
Granulomatous thyroiditis: an unexpected finding leading to the diagnosis of sarcoidosis 176
Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients 176
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 175
Assessment of liver function by the exhaled breath-print during chronic liver disease 169
THU-390 - Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 129
GH-resistance in different stages of chronic liver disease 104
Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery 103
Diabetes in chronic liver disease: from old concepts to new evidence 101
Exhaled breath analysis in hepatology: State-of-the-art and perspectives 99
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination 97
[A 73-year-old woman with vomiting and metabolic alkalosis] 96
Growth hormone-stimulated insulin-like factor-1 and acid labile subunit in chronic liver disease 95
Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people 90
A challenging alfa-fetoprotein in a cirrhotic patient 89
Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor 88
Liver involvement in the course of thymoma-associated multiorgan autoimmunity: The first histological description 88
Diagnostic value of Virtual Touch Quantification (VTQ®) for differentiation of hemangiomas from malignant focal liver lesions 86
Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient 86
The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon 85
METAL METABOLISM IMPAIRMENT IN PATIENTS WITH HEPATIC ENCEPHALOPATHY 84
[A 61-year-old woman with abdominal pain and urination disorders] 83
Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography 83
Portal diameter in the diagnosis of esophageal varices in 266 cirrhotic patients: which role? 80
Determinants of alanine aminotransferase levels in a large population from Southern Italy: relationship between alanine aminotransferase and age 79
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 79
Donna di 35 anni con febbre, dispnea e dolore alla coscia sinistra [A 35-year-old woman with fever, dyspnea, and pain in the left thigh]. 78
Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass 77
[Ramipril and new therapeutic possibilities for ACE-inhibitors] 75
Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis 73
LIVER TOXICITY IN COLORECTAL CANCER PATIENTS TREATED WITH FIRST LINE FOLFIRI-CONTAINING REGIMEN: A SINGLE INSTITUTION EXPERIENCE 73
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis 70
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 69
A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores 65
An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase 64
Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study 63
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 60
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement 59
Combining genetic variants to improve risk prediction for nafld and its progression to cirrhosis: a proof of concept study 56
Biopsy in chronic liver disease: proposal for a shared path between clinicians and pathologists 53
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers 47
TNF-alpha and growth hormone resistance in patients with chronic liver disease 37
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience 37
Lysosomal acid lipase activity is reduced both in cryptogenic cirrhosis and in cirrhosis of known etiology 34
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 34
The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection 33
Pain and Frailty in Hospitalized Older Adults 33
Hepatocellular carcinoma in alcoholic liver disease: current management and recent advances 32
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 32
Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank 32
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 31
Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD 31
Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma 31
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. 31
Lipophagy Impairment Is Associated With Disease Progression in NAFLD 31
Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures 30
The pharmacological treatment of chronic comorbidities in COPD: mind the gap! 29
Infliximab reverses growth hormone resistance associated with inflammatory bowel disease 29
Reelin expression in human liver of patients with chronic hepatitis C infection 29
Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management 29
Rare ATG7 genetic variants predispose patients to severe fatty liver disease 28
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b 27
Subcellular shift of the hepatic growth hormone receptor with progression of hepatitis C virus-related chronic liver disease 27
Renal impairment and anemia during triple therapy 27
The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen 27
Lower schooling, higher hepatitis C virus prevalence in Italy: an association dependent on age 26
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 26
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 26
Prognostic relevance of glomerular filtration rate estimation obtained through different equations in hospitalized elderly patients 26
Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation 26
Hepatic matrix metalloproteinase-10 exerts a hepatoprotective role after acute liver inury 26
Toll-like receptor-4 expression by hepatic progenitor cells and biliary epithelial cells in HCV-related chronic liver disease 26
The Origins of NAFLD: The Potential Implication of Intrauterine Life and Early Postnatal Period 26
Reply 25
Westernization of the Filipino population resident in Rome: obesity, diabetes and hypertension 25
Gas exchanges and pulmonary vascular abnormalities at different stages of chronic liver disease 25
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 25
SINDROME DI SJÖGREN (SS) ASSOCIATA A MALATTIA INFIAMMATORIA PELVICA (PID): DESCRIZIONE DI UN CASO CLINICO 25
Raised C-reactive protein levels in patients with recent onset type 1 diabetes 25
Reply to the Letter: “Low levels of transaminase and mortality risk in older people with special reference to sarcopenia” 25
Totale 8.725
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.775
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.775
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022336 0 2 8 0 3 3 2 6 46 4 4 258
2022/2023112 12 1 6 4 10 2 30 4 3 5 33 2
2023/2024636 26 50 18 62 61 269 2 37 8 40 20 43
2024/20258.381 131 57 236 45 110 186 143 34 482 562 3.017 3.378
2025/20261.071 620 332 119 0 0 0 0 0 0 0 0 0
Totale 10.536